Zinc oxide (ZnO) nanoparticles are the mostly used engineered metal oxide nanoparticles in consumer products. This has increased the likelihood of human exposure to this engineered nanoparticle (ENPs) through different routes. At present, the majority of the studies concerning ZnO ENPs toxicity have been conducted using in vitro and in vivo systems. In this study, for the first time we assessed the effect of ZnO ENPs on the major cellular pathways in the lymphocytes of healthy individuals as well as in susceptible patients suffering from lung cancer, chronic obstructive pulmonary disease (COPD) and asthma. Using the differential expression analysis, we observed a significant (P < 0.05) dose-dependent (10, 20 and 40 µg/ml for 6 h) increase in the expression of tumour suppressor protein p53 (40, 60 and 110%); Ras p21 (30, 52 and 80%); c-Jun N-terminal kinases; JNKs) (28, 47 and 78%) in lung cancer patient samples treated with ZnO ENPs compared to healthy controls. A similar trend was also seen in COPD patient samples where a significant (P < 0.05) dose-dependent increase in the expression of tumour suppressor protein p53 (26, 45 and 84%), Ras p21 (21, 40 and 77%), JNKs (17, 32 and 69%) was observed after 6 h of ZnO ENPs treatment at the aforesaid concentrations. However, the increase in the expression profile of tested protein was not significant in the asthma patients as compared to controls. Our results reiterate the concern about the safety of ZnO ENPs in consumer products and suggest the need for a complete risk assessment of any new ENPs before its use.
Introduction
Nanotechnology has found application in diverse sectors such as energy, electronics, food and agriculture, biomedical devices, imaging, biosensing and chips, environmental clean-up, house hold products, paints, consumer products and sports (1) . Zinc oxide (ZnO) nanoparticles are one of the majorly used engineered nanoparticles (ENPs) in different consumer products. More than 300 companies around the world are producing in excess of 1.2 million tons of ZnO ENPs per year (2) . The increased production and application has also raised the likelihood for ZnO ENPs exposure to humans at various steps of synthesis (laboratory), manufacture (industry), use (consumer products, devices, medicines, etc.) and disposal (3) (4) (5) .
ENPs' behaviour in air is primarily governed by diffusion, agglomeration, particle size, inertia and gravitational forces. The particle diffusion coefficient is inversely proportional to the particle diameter (6, 7) . As the diameter of the particle decreases, the value of the diffusion coefficient increases which results in high mobility and rapid mixing of ENPs in an aerosol. After the release of ENPs in the environment, atmospheric diffusion facilitates the ENPs to spread rapidly from a higher to a lower concentration, thus resulting in rapid dispersion and migration for a large distance from the source (8) . Inhalation is one of the major routes of exposure to the ENPs and is considered to be the primary route by which humans get exposed to the air-borne ENPs. After inhalation, the ENPs are likely to get deposited in different regions of the respiratory tract depending on the particle size (9, 10) . Several kinds of sicknesses can be expected from exposure to ENPs, including asthma, bronchitis, lung and liver cancer and others (5, 11) .
Signal transduction pathways are important mechanisms through which the cell coordinates particular functions by activating the specific membrane receptor in response to an external stimulus. They also release a second messenger which transmits the signal into the cell to produce a physiological response. Our earlier studies have reported that the metal oxide ENPs can induce apoptosis in different cell lines and in vivo models by the activation of extrinsic and/or intrinsic death pathways (12) (13) (14) (15) (16) (17) (18) . It is also established that the apoptotic process is regulated by many other signalling pathways (19) . Ras proteins are a type of G-protein that has been shown to play a key role in signal transduction, proliferation, and malignant transformation (20, 21) . They have also been reported as a biomarker in diseases such as chronic obstructive pulmonary disease (COPD) and lung cancer (22, 23) . It is also established that Ras activates the mitogen activated protein kinase (MAPK) through multiple effectors (24) .
Therefore, in this study we investigated the effects of ZnO ENPs on the lymphocytes isolated from different patients [lung cancer, COPD and asthma] samples and healthy individuals by analysing the differential expression profiling of tumour-related proteins including p53, Ras oncoprotein and other essential proteins that play important roles in extracellular signalling pathways. A schematic representation of the study design is depicted in Figure 1 . The diseases have been diagnosed by the consultant involved in the study (BKJ). For COPD, patients were over 40 years of age with a 10 or more pack per year smoking history, and a fixed spirometric ratio of forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) of <0.7 or radiological evidence of emphysema. Asthma patients were diagnosed by their medical practitioner. These patients have symptoms of intermittent breathlessness, cough and wheeze. They have less than 10 pack per years history of smoking or non-smokers. They have variable and reversible airflow obstruction on spirometer. They also may have atopy such as allergic rhinitis or hay fever or high IgE with eosinophilia. The characteristics of the patient and healthy volunteers are shown in Table 1 .
Peripheral blood lymphocytes were isolated from whole blood using the Lymphoprep method. Briefly, blood was diluted 1:1 in sterile saline (0.9%) and 6 ml of this diluted sample was carefully layered on top of 3 ml of Lymphoprep in 15 ml conical tubes followed by centrifugation for 20 min at 807 g at room temperature. The buffy coat layer of lymphocytes (above the Lymphoprep layer) was then transferred to another tube prefilled with 10 ml of saline and centrifuged at 503 g for 15 min at room temperature. The supernatant was removed without disturbing the pellet which was then cultured in RPMI 1640 medium with l-glutamine (Gibco, Paisley, UK), supplemented with 15% heat inactivated foetal calf serum (Gibco, Paisley, UK), 100 U/ml penicillin (PAA Laboratories GmbH, Pascing, Austria), 100 µg/ml streptomycin (PAA Laboratories GmbH, Pascing, Austria) and 2% phytohaemagglutinin (PHA, Murex Biotech Ltd., Dartford, UK) and incubated at 37°C in a humidified incubator containing 5% CO 2 . 
Treatment of lymphocytes
A stock suspension of ZnO ENPs (80 µg/ml) in RPMI was diluted to different concentrations in complete RPMI. Lymphocyte suspensions (10 6 cells per ml) were exposed to 10, 20 and 40 µg/ml of ZnO ENPs in the presence of complete RPMI media in a total volume of 5 ml for 6 and 12 h at 37°C.
Cell viability
Lymphocyte viability was measured by the Trypan blue dye exclusion test (Phillips, 1973). 10 µl of 0.05% Trypan blue was added to 10 µl of cell suspension and the percentage of cells excluding the dye was estimated using a Neubauer Improved haemocytometer.
Protein isolation and immunoblot analysis
After treatment, cells were centrifuged and the pellets were lysed in lysis buffer (150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 7.5, 2 mM EDTA) containing protease inhibitor cocktail (Sigma, Dorset, UK). Protein concentration was estimated using Bradford's method (Bradford 1976). Protein (50 µg) from control and treated groups was separated on polyacrylamide gel (12%) and transferred to a polyvinylidene difluoride (PVDF) membrane by electroblotting. The membrane was further blocked and incubated with primary antibodies specific for p53, Ras p21, MAPK, extracellular signal-regulated kinases (ERK) and c-Jun N-terminal kinases (JNKs; Millipore, India). Secondary antibodies incubation was done and protein bands were detected using chemiluminescence. Densitometric analysis was carried out using Quantity One Quantitation Software © version 4.3.1 (Bio-Rad, USA).
Statistical analysis
All the experiments were performed in duplicate and repeated at least three times. Results are expressed as means ± SEM of three experiments and data were analysed using one-way analysis of variance with Dunnett's post hoc test to determine significance relative to control. In all cases, P < 0.05 was considered significant.
Results

Characterisation of nanoparticles
The mean hydrodynamic diameter and zeta potential of the ZnO ENPs in RPMI as determined by the DLS measurement was 140-160 nm and −23 mV, respectively whereas, the average size measured by TEM was 27-35 nm (Figure 2 ). Also, in complete RPMI medium the mean hydrodynamic diameter and zeta potential of the ZnO ENPs was 87-96 nm and −18 mV. The ENPs suspensions were stable, mono-dispersed and have a lower polydispersity index (0.187). Additionally, the surface 
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Cell viability
Cell viability of ZnO ENPs treated samples were assessed by Trypan blue dye exclusion test after 6 and 12 h, respectively. The viability of lung cancer patient samples after ZnO ENPs treatment was reduced to 65 and 57% (relative to 100% of control) at concentration 20 and 40 µg/ml after 12 h of exposure. However, the viability of ZnO ENPs treated COPD patient samples were reduced to 67 and 60% (relative to 100% of control) at the aforesaid concentration after 12 h of treatment. No significant cytotoxic effect of ZnO ENPs was observed after 6 h of exposure to different patients with lung disease (Figure 3) and so differential protein analysis was conducted at this exposure time.
Immunoblot analysis
Differential protein expression analysis of p53, Ras p21, MAPK, ERK and JNKs were analysed in ZnO ENPs' treated patient samples by immunoblot analysis. We observed a significant (P < 0.05) dosedependent increase in the expression of tumour suppressor protein p53 (40, 60 and 110%); Ras p21 (30, 52 and 80%); JNKs (28, 47 and 78%); p38 (16, 28 and 43%) in lung cancer patient samples treated with ZnO ENPs at concentrations of 10, 20 and 40 µg/ ml for 6 h. Also in COPD patient samples, a significant (P < 0.05) dose-dependent increase in the expression of tumour suppressor protein p53 (26, 45 and 84%), Ras p21 (21, 40 and 77%), JNKs (17, 32 and 69%), p38 (11, 20 and 43%) were observed after 6 h of ZnO ENPs treatment at aforesaid concentrations. However, the increase in the expression profile of tested protein was not significant in the asthma patients when compared with controls (Figures 4-6) . Also, no changes in phospho-ERK and ERK levels were observed in the lymphocytes of healthy volunteers and in respiratory disease patients on exposure to ZnO NPs. These analysis were performed relative to the untreated control within the group, where untreated cells are considered as a control cells. Also, we observe an increase in expression of tumour suppressor protein p53 (6, 11 and 14%), Ras p21 (7, 10 and 14%), after 6 h of ZnO ENPs treatment to the lymphocytes of healthy volunteers at aforesaid concentrations. Additionally, we observed that the characteristics such as age, gender and ethnicity of the patients and healthy volunteers did not appear to confound interpretation of the above data. However, the smoking habit of the patients and healthy volunteers affected responses non-significantly.
Discussion
This study reveals the effects of ZnO ENPs on peripheral blood lymphocytes of different respiratory disease patients and provides significant insight into the possible mechanism through which ZnO ENPs exert their toxic effects on these cells. Our results demonstrated the overexpression of p53 (tumour suppressor protein) and p21 (Ras oncoprotein) as well as the modulation in some major extracellular signal regulator kinases (ERK), N-terminal kinases JNK and p38 mitogen-activated protein kinases pathways.
Characterisation of ENPs is essential due to the fact that shape, size, surface area, surface charge and monodispersity affect their physiochemical properties and are directly responsible for their differential responses within the biological systems (25) . Hence the ENPs were systematically characterised in dry powder form using TEM and in liquid suspension (culture media) using DLS, respectively, to provide a clear picture of size and other physical properties such as the poly dispersity index (PDI) and zeta potential. These parameters allow better interpretation of the differences in the activity of two different types of particles or particles of the same material having different sizes. The mean hydrodynamic diameter and zeta potential of the ZnO ENPs in RPMI as determined by the DLS measurement was 140-160 nm and −23 mV, respectively whereas, the average size measured by TEM was 27-35 nm (Figure 2 ). Our TEM measurements and DLS analysis showed that ZnO ENPs were stable and monodispersed in culture media. The difference in size measured by different techniques is due to the fact that different size determination methods give different results based on the principles employed (1). DLS measures Brownian motion and subsequent size distribution of an ensemble collection of particles in solution and gives a mean hydrodynamic diameter which is usually larger than the TEM diameter as it includes a few solvent layers (2) during DLS measurement there is a tendency of particles to agglomerate in the aqueous state thereby giving the size of clustered particles rather than individual particles (3) it reports an intensity weighted average hydrodynamic diameter of a collection of particles so any polydispersity of the sample will skew the average diameter towards larger particle sizes (26, 27) .
Considering the relevance of the respiratory system as a route for NPs exposure in humans, the scientific community has focused on the toxicological effects of NPs on animal respiratory models. Such experiments provide the basis to obtain more detail data regarding the hazard of NPs and to extrapolate evaluations for human risk assessment.
The NPs have a tendency to translocate from pulmonary airways into other pulmonary compartments, such as epithelium/ endothelium, connective tissue, the capillary lumen, or into systemic circulation. In fact, it found that NPs were preferentially located in the connective tissue and in the capillary lumen at 1 and 24 h after exposure, respectively. The epithelium and the connective tissues were not deposition sites but only passageways for NPs to reach the capillary circulation. Hence, lymphocytes were used to access the effect of NPs in different respiratory disease patients. Also, a study on carbon nanoparticle exposure in both in vitro and in vivo systems, presents evidence that nanoparticles, accumulated in the plasma membranes of cells, increased alveolar macrophage function with antigen presentation, significantly exacerbated airway hyper-responsiveness, and caused an influx of macrophages into the lungs (28) . It is possible, theoretically, that long-term exposure to nanoparticles may cause serious damage to humans as well as animals. Additionally, to determine the non-cytotoxic concentration of ZnO ENPs on lymphocytes, trypan blue dye exclusion test was performed. Lymphocytes were exposed to ZnO ENPs for 6 and 12 h at 10, 20 and 40 µg/ml concentrations. The data demonstrated a cytotoxic potential of ZnO ENPs at 20 and 40 µg/ml after 12 h of exposure, while after 6 h it was not significant (Figure 3) . Hence, further experiments for differential protein analysis were performed at the non-cytotoxic concentrations, i.e. 10, 20 and 40 µg/ ml for 6 h. The DNA damaging potential of ZnO ENPs in different in vitro and in vivo models through direct interaction with DNA as well as by a secondary genotoxic mechanism is well documented (12, 15, 18) . Also, the accessibility of ZnO ENPs in the nucleus of different cells has been reported (29, 30) . This also increases the likelihood of the interaction of ENPs with different enzymes involved in the detection of DNA breaks (31) . It has recently been shown that the incubation of the ENPs and ions with formamidopyrimidine DNA glycosylase (FPG) enzyme leads to the total loss of the ability of the enzyme to detect oxidatively damaged DNA in the Comet assay (32) . Therefore, in this study the expression of tumour suppressor protein p53 was examined to correlate the DNA damaging potential of ZnO ENPs in different patient samples. The p53 pathway is extremely sensitive to a very small number of DNA strand breaks or singlestranded gaps. This can also be considered as a factor which could be important in the early detection of DNA lesions in tumours (33, 34) . Once induced, p53 regulates the expression of a wide range of genes, leading to the biological outcomes of repair, growth arrest or apoptosis (35) . We observed a dose dependent increase in the expression profile of p53 protein in all sample groups. The induction was more prominent in lung cancer patients than in COPD, asthma and healthy controls. The expression profile of p53 protein was almost comparable in asthma patients and healthy controls (Figure 4 ). Our observations support the DNA damaging potential of the ZnO ENPs.
Further to support the tumorigenic potential of the ZnO ENPs, the expression of Ras oncoprotein was examined. Ras proteins are G proteins that have been shown to play a key role in signal transduction, proliferation, and malignant transformation (24, 36) . It has also been reported as a biomarker in diseases such as COPD and lung cancer (37) . Ras p21 proteins are contained in all eukaryotic cells on the inner surface of the plasma membrane and are found to be activated in many human cancers. Our immunoblot results showed a dose dependent increase in the expression profile of p21 protein in all the sample groups after 6 h treatment of ZnO ENPs. The induction was more pronounced in lung cancer patients than in COPD, asthma patients and healthy controls. However, it was also observed that the basal expression of p21 was higher in the patients suffering from COPD and lung cancer when compared to the healthy controls, respectively ( Figure 5 ). Again, as for p53, the expression profile of p21 was comparable in asthma patients and controls.
It is also established that Ras controls the activity of multiple effectors such as Raf family of protein serine/threonine kinases. Through interaction with A-Raf, B-Raf and Raf-1, Ras activates MAPK kinases (24) . Also, various cellular stimuli such as oxidative stress, reactive oxygen species (ROS) are known to activate the three main cascades of the MAPK pathway (1); the extracellular signal-regulating kinase (ERK1/2) (2), stress activated protein kinase (SAPK)/Jun-N-terminal kinase (JNK), and (3) p38 (19, 38) .
We previously have reported that ZnO and TiO 2 ENP induces the intracellular ROS and oxidative stress in the various cell lines and in an in vivo model, which subsequently leads to the cell death via the mitochondria mediated apoptotic pathway (12, (39) (40) (41) (42) . In this study, we assessed the link of MAPK activation with ZnO ENPs treatment. Our data demonstrated activation of JNK and p38 protein in various sample groups treated with ZnO ENPs (Figure 6 ). However, the expression of ERK in all sample groups was unchanged. These outcomes suggest the possible linkage of ROS in the activation of JNK and p38 pathway. It also supports the role of different kinases in ROS mediated mitochondria dependent cell death pathway. Also, the activation of JNK may further lead to the overexpression of c-jun protein which has a significant role in cell proliferation and apoptosis. A possible mechanism of ZnO ENPs induced molecular perturbation in cell signalling pathways of different patients with lung disease is depicted in Figure 7 .
In conclusion the present investigation, using the differential expression analysis of p53, Ras and cell signalling pathway proteins provides the evidence for the genotoxic and carcinogenic effects of ZnO ENP in healthy individuals as well as in patients suffering from lung cancer, COPD and asthma. It was also observed that the lymphocytes of lung cancer patients were more susceptible to ZnO ENPs exposure than the COPD and asthma patients. In fact in general, asthma patients responded in a similar manner to controls. There appeared to be no confounding effects due to age, gender and with a slight non-significant variation due to smoking. 
